P Conti1, Al Caraffa2, F Mastrangelo3, L Tettamanti4, G Ronconi5, I Frydas6, S K Kritas7, T C Theoharides8. 1. Postgraduate Medical School, University of Chieti, Chieti, Italy. 2. Department of Pharmacy, University of Perugia, Perugia, Italy. 3. Department of Medical Science and Biotechnology, University of Foggia, Foggia, Italy. 4. Department of Medical and Morphological Science, University of Insubria, Varese, Italy. 5. UOS Clinica dei Pazienti del Territorio, Policlinico Gemelli, Rome, Italy. 6. Faculty of Parasitology, Aristotle University of Thessaloniki, Macedonia, Greece. 7. Department of Microbiology, University of Thessaloniki, Thessaloniki, Greece. 8. Department of Integrative Physiology and Pathobiology, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Boston, MA, USA.
Abstract
BACKGROUND: Fibrosis involves the activation of inflammatory cells, leading to a decrease in physiological function of the affected organ or tissue. AIMS: To update and synthesize relevant information concerning fibrosis into a new hypothesis to explain the pathogenesis of fibrosis and propose potential novel therapeutic approaches. MATERIALS AND METHODS: Literature was reviewed and relevant information is discussed in the context of the pathogenesis of fibrosis. RESULTS: A number of cytokines and their mRNA are involved in the circulatory system and in organs of patients with fibrotic tissues. The profibrotic cytokines are generated by several activated immune cells, including fibroblasts and mast cells (MCs), which are important for tissue inflammatory responses to different types of injury. MC-derived TNF, IL-1, and IL-33 contribute crucially to the initiation of a cascade of the host defence mechanism(s), leading to the fibrosis process. Inhibition of TNF and inflammatory cytokines may slow the progression of fibrosis and improve the pathological status of the affected subject. IL-37 is generated by various types of immune cells and is an IL-1 family member protein. IL-37 is not a receptor antagonist; it binds IL-18 receptor alpha (IL-18Rα) and delivers the inhibitory signal by using TIR8. It has been shown that IL-37 can be protective in inflammation and injury, and inhibits both innate and adaptive immunity. DISCUSSION: IL-37 may be useful for suppression of inflammatory diseases induced by inhibiting MyD88-dependent TLR signalling. In addition, IL-37 downregulates NF-κB induced by TLR2 or TLR4 through a mechanism dependent on IL-18Rα. CONCLUSION: This review summarizes current knowledge on the role of MC in inflammation and tissue/organ fibrosis, with a focus on the therapeutic potential of IL-37-targeting cytokines.
BACKGROUND: Fibrosis involves the activation of inflammatory cells, leading to a decrease in physiological function of the affected organ or tissue. AIMS: To update and synthesize relevant information concerning fibrosis into a new hypothesis to explain the pathogenesis of fibrosis and propose potential novel therapeutic approaches. MATERIALS AND METHODS: Literature was reviewed and relevant information is discussed in the context of the pathogenesis of fibrosis. RESULTS: A number of cytokines and their mRNA are involved in the circulatory system and in organs of patients with fibrotic tissues. The profibrotic cytokines are generated by several activated immune cells, including fibroblasts and mast cells (MCs), which are important for tissue inflammatory responses to different types of injury. MC-derived TNF, IL-1, and IL-33 contribute crucially to the initiation of a cascade of the host defence mechanism(s), leading to the fibrosis process. Inhibition of TNF and inflammatory cytokines may slow the progression of fibrosis and improve the pathological status of the affected subject. IL-37 is generated by various types of immune cells and is an IL-1 family member protein. IL-37 is not a receptor antagonist; it binds IL-18 receptor alpha (IL-18Rα) and delivers the inhibitory signal by using TIR8. It has been shown that IL-37 can be protective in inflammation and injury, and inhibits both innate and adaptive immunity. DISCUSSION: IL-37 may be useful for suppression of inflammatory diseases induced by inhibiting MyD88-dependent TLR signalling. In addition, IL-37 downregulates NF-κB induced by TLR2 or TLR4 through a mechanism dependent on IL-18Rα. CONCLUSION: This review summarizes current knowledge on the role of MC in inflammation and tissue/organ fibrosis, with a focus on the therapeutic potential of IL-37-targeting cytokines.
Authors: S Marinari; V De Iuliis; V Dadorante; S Colella; A Marino; A Nunziata; V Flati; M Caruso; A Pennelli; F De Benedetto; S Matera; S Capodifoglio; S Martinotti; S Caputi; E Toniato Journal: J Biol Regul Homeost Agents Date: 2017 Jan-Mar Impact factor: 1.711
Authors: Alexandra Taracanova; Mihail Alevizos; Anna Karagkouni; Zuiy Weng; Errol Norwitz; Pio Conti; Susan E Leeman; Theoharis C Theoharides Journal: Proc Natl Acad Sci U S A Date: 2017-05-01 Impact factor: 11.205
Authors: Dolores M Cortez; Marc D Feldman; Srinivas Mummidi; Anthony J Valente; Bjorn Steffensen; Matthew Vincenti; Jeffrey L Barnes; Bysani Chandrasekar Journal: Am J Physiol Heart Circ Physiol Date: 2007-10-05 Impact factor: 4.733
Authors: P Conti; Al Caraffa; F Mastrangelo; L Tettamanti; G Ronconi; I Frydas; S K Kritas; T C Theoharides Journal: Cell Prolif Date: 2018-07-30 Impact factor: 8.755
Authors: Pio Conti; Luisa Stellin; Alesssandro Caraffa; Carla E Gallenga; Rhiannon Ross; Spyros K Kritas; Ilias Frydas; Ali Younes; Paolo Di Emidio; Gianpaolo Ronconi Journal: Int J Mol Sci Date: 2020-06-16 Impact factor: 5.923